KR830002030A - 고(高) 콜레스테롤혈증 치료제, 모나콜린 k의 제조방법 - Google Patents

고(高) 콜레스테롤혈증 치료제, 모나콜린 k의 제조방법 Download PDF

Info

Publication number
KR830002030A
KR830002030A KR1019800000654A KR800000654A KR830002030A KR 830002030 A KR830002030 A KR 830002030A KR 1019800000654 A KR1019800000654 A KR 1019800000654A KR 800000654 A KR800000654 A KR 800000654A KR 830002030 A KR830002030 A KR 830002030A
Authority
KR
South Korea
Prior art keywords
culture medium
methanol
producing
monacus
genus
Prior art date
Application number
KR1019800000654A
Other languages
English (en)
Other versions
KR830002801B1 (ko
Inventor
아끼라 엔도
Original Assignee
가와무라 요시부미
상꾜 가부시끼 가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가와무라 요시부미, 상꾜 가부시끼 가이샤 filed Critical 가와무라 요시부미
Publication of KR830002030A publication Critical patent/KR830002030A/ko
Application granted granted Critical
Publication of KR830002801B1 publication Critical patent/KR830002801B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/145—Fungal isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/645—Fungi ; Processes using fungi

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

고(高) 콜레스테룰혈증 치료제, 모나콜린 K의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 본 발명에 따른 모나콜린 K의 자외선 스펙트럼.
제2도는 본 발며에 따른 모나콜린 K의 적외선 스펙트럼.
제3도는 내부 표준으로서 테트라메틸실란을 사용하는 중수소클로로포름 중에서 60MHZ 양성자를 사용하여 본 발명에 따른 모나콜린 K의 핵자기공명 스펙트럼.
제4도는 중수소메탄올 중에서 Bc를 사용하여 본 발명에 따른 모나콜린 K의 핵자기공명 스펙트럼.

Claims (2)

  1. 모나스쿠스 속에 속하는 모나클린 K생성 미생물을 배양기중에서 백양시킨 다음에, 배양기로부터 모나콜린 K을 단리시킴을 특징으로 하는 모나콜린 K의 제조방법.
  2. 모나스쿠스 속에 속하는 적당한 미생물을 배양기 중에서 배양시킨 다음에, 상기 배양기로부터 하기의 특징을 갖는 화합물을 단리시킴을 특징으로 하는 고 콜레스테롤 혈증 치료제의 제조방법.
    원소 분석치 : C, 71.56% H, 8.85% O, 19.59%
    분자량 : 404(질량분석법에 의함)
    분자식 : C24H3605.
    비선광도 : [α]25 D=+307.6(c==1,메탄올).
    융점 : 157~159°C(분해).
    자외선 흡수 스펙트럼 : 제1도에 도시함.
    적외선 흡수 스펙트럼 : 제2도에 도시함.
    핵자기공명 스펙트럼(60MHz 양성자) : 제3도에 도시함(내부 표준으로서 테트라메틸실란을 사용하여 중수소 클로로포름 중에서 측정).
    핵자기공명 스펙트럼(13c) : 제4도에 도시함(중수소 메탄올 중에서)
    용해도 : 가용성;메탄올, 에탄올, 프로판올, 아세톤, 초산에틸, 클로로포름 및 벤젠.
    불용성;핵산 및 석유에테르.
    성질 및 형상 : 중성, 무색결정.
    박층 크로마토그래피 : 실리카겔(Merck & Co., Ltd. 제; No. 5715 Kieselgel 60 F 254)을 사용하여 염화메틸렌과 아세톤(4:1용적비)와의 혼합물로 전개시킴. Rf=0.47에서 단일점이 나타남.
    ※ 참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019800000654A 1979-02-20 1980-02-19 고(高) 콜레스테롤혈증치료제, 모나콜린 k의 제조방법 KR830002801B1 (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP54017856A JPS5925599B2 (ja) 1979-02-20 1979-02-20 新生理活性物質モナコリンｋおよびその製造法

Publications (2)

Publication Number Publication Date
KR830002030A true KR830002030A (ko) 1983-05-21
KR830002801B1 KR830002801B1 (ko) 1983-12-16

Family

ID=11955290

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019800000654A KR830002801B1 (ko) 1979-02-20 1980-02-19 고(高) 콜레스테롤혈증치료제, 모나콜린 k의 제조방법

Country Status (27)

Country Link
JP (1) JPS5925599B2 (ko)
KR (1) KR830002801B1 (ko)
AT (1) AT373915B (ko)
AU (1) AU532626B2 (ko)
BE (1) BE881825A (ko)
CA (1) CA1129794A (ko)
CH (1) CH645890A5 (ko)
DD (1) DD154494A5 (ko)
DE (2) DE3051175C2 (ko)
DK (2) DK149095C (ko)
ES (1) ES8103171A1 (ko)
FI (1) FI66427C (ko)
FR (1) FR2449685B1 (ko)
GB (1) GB2046737B (ko)
HU (1) HU182069B (ko)
IE (1) IE49743B1 (ko)
IT (1) IT1175260B (ko)
MX (1) MX6314E (ko)
NL (1) NL191540C (ko)
NO (1) NO153974C (ko)
NZ (1) NZ192919A (ko)
PH (1) PH15145A (ko)
PL (1) PL124304B1 (ko)
SE (1) SE453301B (ko)
SG (1) SG6784G (ko)
SU (2) SU1158048A3 (ko)
ZA (1) ZA80962B (ko)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55150898A (en) * 1979-05-11 1980-11-25 Sankyo Co Ltd Preparation of a new physiologically active substance mb-530b
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS5621594A (en) * 1979-07-27 1981-02-28 Sankyo Co Ltd Mb-530b carboxylic acid metal salt and its preparation
PT72394B (en) * 1980-02-04 1982-09-06 Merck & Co Inc Process for preparing dihydro and tetrahydromevinoline hypocholesterolimics
AU548996B2 (en) * 1980-02-04 1986-01-09 Merck & Co., Inc. Tetrahydro-2h-pyran-2-one derivatives
JPH0692381B2 (ja) * 1980-03-31 1994-11-16 三共株式会社 Ｍｂ−５３０ａ誘導体
JPS56142236A (en) 1980-04-08 1981-11-06 Sankyo Co Ltd Ml-236a and mb-530a derivative
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
JPS5835144A (ja) * 1981-08-27 1983-03-01 Sankyo Co Ltd Ｍｂ−５３０ｂ誘導体およびその製造法
US4782084A (en) * 1987-06-29 1988-11-01 Merck & Co., Inc. HMG-COA reductase inhibitors
US4997848A (en) * 1987-10-27 1991-03-05 Sankyo Company, Limited Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition
CA2062023A1 (en) 1992-02-10 1993-08-11 Jagroop S. Dahiya Novel fungal strains and use thereof in antibiotic production
EP0629184A1 (en) * 1992-03-04 1994-12-21 Fujisawa Pharmaceutical Co., Ltd. TETRALIN DERIVATIVES AS HMG-CoA REDUCTASE INHIBITORS
FI932188A (fi) 1992-05-15 1993-11-16 Sankyo Co Oktahydronaftalenoximderivat foer inhibering av kolesterolbiosyntesen, deras framstaellning och anvaendning
US6812007B1 (en) * 1992-11-04 2004-11-02 Keri Vilmos Process for the isolation and purification of mevinolin
HU210867B (en) * 1992-11-04 1995-10-30 Biogal Gyogyszergyar Method for extraction and purification of mevinolin from culture medium
SI9300303A (en) * 1993-06-08 1994-12-31 Krka Tovarna Zdravil Process for isolation of hypolipemic effective substance
US5409820A (en) * 1993-08-06 1995-04-25 Apotex, Inc. Process for the production of lovastatin using Coniothyrium fuckelii
US7238348B2 (en) 1996-09-30 2007-07-03 Beijing Peking University Wbl Corporation Ltd. Method of treatment of osteoporosis with compositions of red rice fermentation products
US6046022A (en) 1996-09-30 2000-04-04 Peking University Methods and compositions employing red rice fermentation products
IL132822A0 (en) 1998-03-20 2001-03-19 Biogal Gyogyszergyar Metabolic controlled fermentation procedure for the manufacture of lovastatin hydroxy acid
IL151290A0 (en) 2000-02-24 2003-04-10 Biogal Pharmaceutical Co Ltd Method of purifying a fermentation broth
JP2003525935A (ja) 2000-03-03 2003-09-02 ビオガル ジョジセルジャール アール テー． 低下したレベルの二量体不純物を伴うロバスタチン及びシンバスタチンの精製方法
KR20010095780A (ko) * 2000-04-12 2001-11-07 나가오카 마사시 배아 홍국
IN192861B (ko) 2000-06-30 2004-05-22 Ranbaxy Lab Ltd
DE60218822T2 (de) * 2001-02-09 2007-07-12 Unilever N.V. Nahrungsmittel enthaltend sojaprotein und statin
KR100379075B1 (en) 2002-03-07 2003-04-08 Jinis Biopharmaceuticals Co Method for producing low cholesterol animal food product and food product therefrom
KR20020093147A (ko) * 2002-05-30 2002-12-13 지니스생명공학 주식회사 성인병 예방 및 치료 보조제
KR100710500B1 (ko) 2005-05-18 2007-04-24 고려대학교 산학협력단 홍국균을 이용한 모나콜린 ｋ 생산방법
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2373609B1 (en) 2008-12-19 2013-10-16 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
RO128803A0 (ro) 2012-10-12 2013-09-30 Ion Gigel Fulga Compoziţie pentru tratamentul sau prevenirea dislipidemiilor
CN110331151A (zh) * 2019-04-11 2019-10-15 北京工商大学 紫色红曲菌mokH基因过表达菌株的构建方法
CN111297938A (zh) * 2020-03-11 2020-06-19 北京康立生医药技术开发有限公司 一种辅助降血脂组合物中洛伐他汀的检测方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (ko) * 1974-06-07 1981-03-18
JPS55150898A (en) * 1979-05-11 1980-11-25 Sankyo Co Ltd Preparation of a new physiologically active substance mb-530b
IL60219A (en) * 1979-06-15 1985-05-31 Merck & Co Inc Hypocholesteremic fermentation products of the hmg-coa reductase inhibitor type,their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
DK73080A (da) 1980-08-21
ZA80962B (en) 1981-03-25
JPS5925599B2 (ja) 1984-06-19
PH15145A (en) 1982-08-24
NL191540C (nl) 1995-09-04
HU182069B (en) 1983-12-28
DE3006216C2 (de) 1985-10-31
DE3051175C2 (ko) 1989-12-21
GB2046737B (en) 1983-01-12
AU5567380A (en) 1980-08-28
IE49743B1 (en) 1985-12-11
SE8001339L (sv) 1980-08-21
KR830002801B1 (ko) 1983-12-16
DK21889D0 (da) 1989-01-18
ES488796A0 (es) 1981-02-16
MX6314E (es) 1985-04-01
CA1129794A (en) 1982-08-17
ES8103171A1 (es) 1981-02-16
SE453301B (sv) 1988-01-25
IT1175260B (it) 1987-07-01
SU969702A1 (ru) 1982-10-30
CH645890A5 (de) 1984-10-31
NZ192919A (en) 1984-07-06
AU532626B2 (en) 1983-10-06
ATA92980A (de) 1983-07-15
FR2449685B1 (fr) 1985-06-28
PL124304B1 (en) 1983-01-31
DK149095B (da) 1986-01-20
NO153974C (no) 1986-06-25
FI800506A (fi) 1980-08-21
GB2046737A (en) 1980-11-19
DK149095C (da) 1986-06-16
NL8001041A (nl) 1980-08-22
AT373915B (de) 1984-03-12
FI66427B (fi) 1984-06-29
SG6784G (en) 1985-02-08
PL222120A1 (ko) 1980-10-20
NO153974B (no) 1986-03-17
NL191540B (nl) 1995-05-01
IT8067262A0 (it) 1980-02-20
SU1158048A3 (ru) 1985-05-23
DD154494A5 (de) 1982-03-24
FI66427C (fi) 1984-10-10
FR2449685A1 (fr) 1980-09-19
DK21889A (da) 1989-01-18
IE800321L (en) 1980-08-20
BE881825A (fr) 1980-08-20
DE3006216A1 (de) 1980-09-04
JPS55111790A (en) 1980-08-28
NO800451L (no) 1980-08-21

Similar Documents

Publication Publication Date Title
KR830002030A (ko) 고(高) 콜레스테롤혈증 치료제, 모나콜린 k의 제조방법
Wall et al. Isolation, structure, and biological activity of several metabolites of. DELTA. 9/tetrahydrocannabinol
Niwa et al. Biosynthesis of daphnilactone-B
KR880010131A (ko) 항생물질 버미스포린, 그의 제조방법 및 그것을 활성 항균제로서 포함하는 약제 조성물
Granström et al. The Structure of the Main Urinary Metaboilite of Prostaglandin F2α in the Guinea Pig
Moriyama et al. New sesquiterpene lactones of eremophilane-type from Ligularia Fauriei (Fr.) Koidz.
Cane et al. Stereochemical studies of isoprenoid biosynthesis. Biosynthesis of fomannosin from [1, 2-13C2] acetate
Schroeder et al. Inhibition of aflatoxin production and tentative identification of an aflatoxin intermediate “versiconal acetate” from treatment with dichlorvos
Kazlauskas et al. Five new C26 tetracyclic terpenes from a sponge (Lendenfeldia sp.)
Lee et al. Antitumor agents I: Angustibalin, a new cytotoxic sesquiterpene lactone from Balduina angustifolia (Pursh.) robins
Chexal et al. Gilmicolin and Mycorrhizinol, Two New Metabolites of Gilmaniella humicolaBARRON
CN109942658B (zh) 一类杂萜化合物及其制备方法与应用和抗肿瘤的药物
Nomura et al. Constituents of the Chinese Crude Drug „Sāng-Bái-Pí”(Morus Root Bark)
Otten et al. Microbial transformations of natural antitumor agents: conversion of lapachol to dehydro-alpha-lapachone by Curvularia lunata
Silva et al. Purification and characterization of mononocardomycoloylglycerol from Nocardia rhodochrous
Maes et al. Polyketide-derived fungal metabolites from Bipolaris sorokiniana and their significance in the biosynthesis of sterigmatocystin and aflatoxin B 1
Shoyama et al. Cannabis. XIII. Two new spiro-compounds, cannabispirol and acetyl cannabispirol
Rikisaku et al. Structural elucidation of alterporriol B, a novel metabolic pigment produced by Alternaria porri (Ellis) ciferri
Sugama et al. A glycoside from dried roots of Cynanchum paniculatum
Piers et al. Conversion of (+)-α-cyperone and (–)-7-epi-α-cyperone into hydroazulenederivatives
Hussain et al. Bisbenzylisoquinoline alkaloids from Thalictrum cultratum. The structures of thalrugosinone and thalpindione
Kaouadji et al. Mycosporulone, a metabolite from Coniothyrium sporulosum
Raju et al. Microbial Transformations of Natural Antitumor Agents. 20. Glucosylation of Viridi-catumtoxin
Van Eijk et al. Naphthoquinone derivatives from the fungus Hendersonula toruloidea
YAMADA et al. Studies on Marine Natural Products. I. 13-Membered Carbocyclic Cembranolide Diterpenes from the Soft Coral Lobophytum pauciflorum (Ehrenberg)